<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20090629162806+02'00'</creation_date><modification_date>D:20090629162808+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-283_h_dec_15.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>commission of the european communities</p><p>brussels, 24.6.2009 c(2009)5206 
 not for publication</p></section><section><header>commission decision of 24.6.2009 
 on the renewal of the marketing authorisation for the medicinal product for human 
 use &quot;ariclaim - duloxetine hydrochloride&quot;, granted by decision c(2004)3160</header><p>(only the dutch text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 24.6.2009 
 on the renewal of the marketing authorisation for the medicinal product for human 
 use &quot;ariclaim - duloxetine hydrochloride&quot;, granted by decision c(2004)3160 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, and in particular article 10(2) thereof, having regard to the application submitted by eli lilly nederland b.v., on 14 january 
 2009, under article 14(2) of regulation (ec) no 726/2004 with a view to the renewal of 
 the marketing authorisation for the medicinal product &quot;ariclaim - duloxetine 
 hydrochloride&quot; 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 23 april 2009, 
 whereas: 
 (1)</p><p>on the basis of a re-evaluation by the agency of the risk-benefit balance 
 following the consideration of a consolidated file, it appears that the medicinal 
 product &quot;ariclaim - duloxetine hydrochloride&quot;, entered in the community register 
 of medicinal products under number(s) eu/1/04/283/008-012 and authorised by 
 commission decision c(2004)3160 of 11 august 2004, complies with the 
 requirements set out in directive 2001/83/ec of the european parliament and of 
 the council of 6 november 2001 on the community code relating to medicinal 
 products for human use
 2. (2)</p><p>the marketing authorisation which expires on 13 august 2009 should therefore 
 be renewed. 
 (3)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use,</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>has adopted this decision: article 1 the marketing authorisation granted by decision c(2004)3160 of 11 august 2004 which expires on 13 august 2009 is renewed. 
 article 2 decision c(2004)3160 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision; 
 2) annex ii is replaced by the text set out in annex ii to this decision; 
 3) annex iii is replaced by the text set out in annex iii to this decision. 
 article 3 this decision is addressed to eli lilly nederland b.v., grootslag 1-5, 3991 ra houten, nederland. 
 done at brussels, 24.6.2009 
 for the commission heinz zourek 
 director-general</p></section></body></xml>